Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Attention in Alzheimer's Disease
NCT00216515Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2004
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 4, open-label, single-arm trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoints: Visual Continuous Performance Test, Visual Span Test and 2 more. Started Mar 2004; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00216515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216515.